MIR21

Overview

MIR21 encodes microRNA-21 (miR-21), a small non-coding RNA that functions as a post-transcriptional regulator of gene expression. Like other microRNAs, it acts by binding target messenger RNAs and modulating their stability or translation, thereby influencing cellular programs such as proliferation, apoptosis, and stress responses. In biomedical research, miR-21 is widely studied as a cancer-associated biomarker and regulatory molecule, particularly in breast cancer and other solid tumors.

Recent studies have continued to use MIR21 as a model target for both mechanistic cancer research and ultrasensitive molecular detection. In these contexts, miR-21 is frequently discussed alongside breast cancer, triple-negative breast adenocarcinoma, colorectal, head/neck, melanoma, and prostate tumors, reflecting its broad relevance in oncology. It has also been investigated in relation to pathways and molecular factors such as PTEN and the SIRT1/HIF-1α pathway, consistent with its role in tumor biology and treatment response.

Recent Publications Summary

Recent investigations into microRNA-21 (miR-21) have primarily focused on developing sensitive detection methodologies for cancer diagnosis and disease monitoring. Multiple studies established miR-21 as a valuable biomarker across diverse cancer types, including breast cancer, urothelial carcinoma, and hepatocellular carcinoma. A range of novel biosensing platforms have been developed to detect miR-21 in clinical samples, employing diverse transduction mechanisms. These include triboelectric nanogenerator-based self-powered sensors that detected miR-21 at 328 pM in artificial urine 42555722Aug, lateral flow assay strips using AND logic gating that enabled visual detection alongside miR-155 for breast cancer diagnosis 42550284Aug, and quantum dot DNA nanospheres achieving attomolar-level sensitivity (30 aM) in clinical urine samples 42287261Jun. CRISPR-based platforms have emerged as particularly versatile tools, with the topology-gated Topo-CRISPR system achieving attomolar sensitivity within 25 minutes without preamplification, demonstrating clinical performance comparable to reverse transcription quantitative polymerase chain reaction 42479891Jul, and the split CRISPR/Cas12a (SCAN) platform achieving femtomolar detection (2 fM) through integration with catalytic hairpin assembly 42424186Jul.

Beyond optical and molecular approaches, electrochemical and plasmonic sensing technologies have demonstrated exceptional analytical performance. An integrated electrochemical computational model framework detected miR-21 at 5.0 × 10⁻¹⁸ M with robust anti-interference in complex matrices such as serum and saliva 42119575May, while machine learning-assisted plasmonic sensing using Au@Ag-Ti3C2Tx MXene interfaces achieved femtomolar detection in saliva matrices 41895231Mar. A gold nanoparticle-based CRISPR-Cas12a assay enabled rapid visual detection with femtomolar sensitivity for hepatocellular carcinoma-related miRNAs 42263201Jun, and a dichromatically encoded DNA nanodevice (DRIVE) integrating catalytic hairpin assembly achieved multicolor signal amplification for triple-negative breast cancer subtyping 42071303May. A photonic crystal hydrogel biosensor enabled smartphone-based readout with nanomolar sensitivity in saliva and serum 41941853Apr.

Clinical applications emphasized miR-21's utility in liquid biopsy and noninvasive diagnostics. Urinary miR-21 detection proved particularly promising for bladder cancer screening, with a dual-channel quantum dot nanosphere platform demonstrating strong concordance with quantitative polymerase chain reaction in urine samples from patients with bladder cancer, other urological diseases, and healthy controls 42287261Jun. Multiple sensing platforms were validated on clinical specimens, including those monitoring urinary ATP and miR-21 elevation in cystitis patients 42555722Aug and breast cancer-derived exosomal miRNAs, where miR-21 and miR-27a were quantified in MCF-7 and MDA-MB-231 cell-derived exosomes using competitive magneto enzyme-linked assays 41605075Jan.

Complementary studies investigated miR-21 modulation through therapeutic interventions. CRISPR/Cas9-mediated editing of miR-21 was applied in high-grade urothelial carcinoma cells to assess its role as an oncogenic regulator 42319574Jun. In triple-negative breast cancer models, betulinic acid treatment induced downregulation of miR-21 alongside increased apoptosis, with molecular docking studies revealing binding interactions with downstream targets HIF1A, PDCD4, PTEN, and SMAD7 42143107May. A salvianolic acid C-based approach targeted the miR-21/A20 pathway to attenuate podocyte injury in diabetic kidney disease, highlighting miR-21's broader pathogenic role beyond malignancy 41903586Mar.

What Changes, What Holds

1. Triboelectric nanogenerators and quantum dot platforms establish diverse measurement modalities for miR-21 detection at clinical scales
METHOD Multiple biosensing technologies now enable miR-21 quantitation at attomolar sensitivity in urine 42555722Aug42287261Jun. The Overview recognizes miR-21 as studied for ultrasensitive detection but does not describe emerging technologies or practical sensitivity ceilings. Convergence toward high-sensitivity measurement across independent platforms suggests miR-21 detection is transitioning from research tool to accessible clinical measurement capability.

2. Electrochemical, plasmonic, and nanodevice platforms extend miR-21 detection across diverse specimen matrices and signal transduction mechanisms
METHOD Integrated electrochemical models and DNA nanodevices detect miR-21 in serum, saliva, and cell-derived exosomes with femtomolar sensitivity 42119575May42071303May. The Overview describes miR-21 detection as a research application but does not specify technical platforms or compatibility across biological matrices. These methodologies demonstrate that miR-21 measurement is achievable across multiple specimen types and transduction modes, broadening clinical implementation pathways beyond single-platform approaches.

3. Urinary miR-21 quantitation enables noninvasive bladder cancer screening with performance comparable to quantitative PCR
NEW DIRECTION Quantum dot nanosphere platforms demonstrate concordance with quantitative PCR for urinary miR-21 detection in bladder cancer patients, other urological diseases, and controls 42287261Jun. The Overview identifies miR-21 as a cancer biomarker broadly but does not establish liquid biopsy or urinary detection for specific cancer screening applications. Noninvasive urinary biomarker detection addresses a gap in the baseline account, positioning miR-21 as a potential screening tool for bladder cancer beyond existing oncology applications.

4. Downregulation of miR-21 through genetic editing or small-molecule treatment reduces proliferation and induces apoptosis in cancer models
NEW DIRECTION CRISPR/Cas9 editing in urothelial carcinoma and betulinic acid treatment in triple-negative breast cancer downregulate miR-21 alongside apoptosis 42319574Jun42143107May. The Overview describes miR-21 as an oncogenic regulator but does not establish therapeutic targeting as a treatment strategy. Demonstration of therapeutic benefit through miR-21 suppression transforms the entity from biomarker into intervention target, with extension to non-cancer disease including diabetic kidney disease suggesting broader therapeutic potential.

Overview update candidates: miR-21's utility in liquid biopsy and urinary biomarker detection for cancer screening; therapeutic potential through miR-21 downregulation in cancer and disease models.